



**CORPORATE OFFICE OF GOVERNMENT AFFAIRS – EUROPE**

Mr. N. Rossignol  
European Commission  
Enterprise and Industry DG  
Pharmaceutical Unit  
BREY 10/128  
B-1049 Brussels  
e-mail: [Nicolas.rossignol@ec.europa.eu](mailto:Nicolas.rossignol@ec.europa.eu)

Brussels, 18 December 2007

Dear Sir,

*Re : Comments on proposal for revision of the variations regulations*

Please find attached Johnson & Johnson's response to the Proposal for Revision of the Variations Regulations.

As the world's most comprehensive and broadly based manufacturer of healthcare products, as well as a provider of related services, for the consumer, pharmaceutical and medical devices and diagnostics markets, we welcome the opportunity to share our views and suggestions in relation to this important initiative. Given the varied nature of our healthcare business, we believe that we have an important role to play in the development and implementation of policy and debate in this important field.

We hope that the Commission will take our views into account and we look forward to contributing constructively to the further development of EU level initiatives in the area of regulations.

Should you have any questions, please do not hesitate to contact me at the address below.

Yours sincerely,

Scott C. Ratzan MD, MPA  
Vice President, Pharmaceuticals and Global Health  
Government Affairs, EMEA

e-mail: [sratzan@jppbe.jnj.com](mailto:sratzan@jppbe.jnj.com)